Featured Research

from universities, journals, and other organizations

Once-a-week treatment of tuberculosis one step closer, South African researchers say

Date:
February 17, 2010
Source:
Council for Scientific and Industrial Research
Summary:
Researchers in South Africa are one step closer to providing tuberculosis (TB) sufferers with a once-a-week medicinal regime rather than their current daily doses. A preclinical efficacy study demonstrated that tuberculosis drugs given once a week over a four-week period were just as effective as daily doses of the drug over the same period when a new drug delivery technology is used.

Researchers at the Council for Scientific and Industrial Research (CSIR) are one step closer to providing tuberculosis (TB) sufferers with a once-a-week medicinal regime rather than their current daily doses.

A preclinical efficacy study demonstrated that TB drugs given once a week over a four-week period were just as effective as daily doses of the drug over the same period when the CSIR teams drug delivery technology is used.

The biggest problem with the current therapeutic regimen for TB is that the drugs should be taken once a day for a period of six to nine months in order to be effective. Also, according to the World Health Organization (WHO) Direct Observed Treatment shortcourse DOTs programme, the drugs need to be taken in the presence of a healthcare practitioner, says Dr Boitumelo Semete, senior researcher in the drug delivery programme at the CSIR.

Due to logistics, cost and other considerations, this is problematic for South African patients, especially in rural areas. As these drugs furthermore have a number of nasty side effects, many patients never complete their treatment course. This slims down their chances of recovery quite significantly, says Semete.

She explains that to improve patient compliance with TB treatment, the CSIR team is developing a way that will ensure that the antibiotic drugs are released and taken up in the affected cells over a longer period of time, using nanoparticles. This means that patients will only have to take the drugs once a week instead of daily and the associated side-effects will be less. It is also hoped that, due to more effective delivery and improved bioavailability of the drug, the total treatment period will be significantly reduced.

The preclinical efficacy study just completed is strong confirmation of the potential of the drug delivery technology. While there is still a long road ahead before we can take our technology to human clinical trials and eventually make the treatment available to patients, we have just reached a significant milestone along the way, she says.

The CSIR team, under leadership of Dr Hulda Swai, is developing a polymeric anti-TB nanodrug delivery system. Four different types of TB drugs are encapsulated in nano-sized polymeric particles. The drug will still be taken orally, but the particles will end up in systemic circulation in the body for a longer period instead of being eliminated by the body too quickly. This enables a sustained release into the body over longer periods with a gradual uptake of the antibiotics into the cells.

This methodology not only reduces the amount of drugs needed to effectively treat the disease, but also the associated side-effects and costs due to a lesser frequency of drugs taken.

To demonstrate the feasibility of this technology, the team encapsulated anti-TB drugs into polymeric nanoparticles of an average size on 250nm. An efficacy study was then conducted at the University of Cape Town. In this study, mice infected with TB were treated with the current anti-TB drug formulation once every day for four weeks as per standard regimen. A control group of TB-infected mice were treated with a once-a-

week

dose of the nanoencapsulated anti-TB drugs over the same four-

week

period. The encapsulated drugs resulted in the same reduction in bacterial burden as the conventional therapy.


Story Source:

The above story is based on materials provided by Council for Scientific and Industrial Research. Note: Materials may be edited for content and length.


Cite This Page:

Council for Scientific and Industrial Research. "Once-a-week treatment of tuberculosis one step closer, South African researchers say." ScienceDaily. ScienceDaily, 17 February 2010. <www.sciencedaily.com/releases/2010/02/100217093940.htm>.
Council for Scientific and Industrial Research. (2010, February 17). Once-a-week treatment of tuberculosis one step closer, South African researchers say. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2010/02/100217093940.htm
Council for Scientific and Industrial Research. "Once-a-week treatment of tuberculosis one step closer, South African researchers say." ScienceDaily. www.sciencedaily.com/releases/2010/02/100217093940.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins